Puma Biotechnology Inc (PBYI) Covered Calls
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products for cancer care. Its lead product is an oral medicine used as an extended adjuvant treatment for adults with early-stage HER2-positive breast cancer. By targeting specific pathways that drive tumor growth, the company provides therapeutic options for aggressive cancers. Puma also conducts clinical trials to expand its treatments into other HER2-mutated tumor types.
You can sell covered calls on Puma Biotechnology Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PBYI (prices last updated Fri 9:55 AM ET):
| Puma Biotechnology Inc (PBYI) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 7.28 | -0.12 | 7.27 | 7.32 | 37K | 12 | 0.4 |
| Covered Calls For Puma Biotechnology Inc (PBYI) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 7.5 | 0.50 | 6.82 | 7.3% | 121% | |
| Jun 18 | 7.5 | 0.00 | 7.32 | 0.0% | 0.0% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Puma Biotechnology, Inc. operates as a development-stage biopharmaceutical entity with a heavy focus on in-licensing and advancing drug candidates for oncology. The company strategy centers on identifying promising compounds that have already undergone initial testing and utilizing its expertise to navigate them through late-stage clinical trials and regulatory approval. This focused approach allows the firm to concentrate its resources on specialized cancer therapies that address high unmet medical needs.
Core Business and Products
The company lead product is NERLYNX (neratinib), an oral medication specifically indicated for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. It also has applications for metastatic HER2-positive breast cancer in combination with other agents. Beyond its lead product, the company is actively researching the use of neratinib in other HER2-mutated cancers, including lung and bladder cancers. The business operates by partnering with global distributors and healthcare providers to ensure patient access to these targeted therapies.
Competitive Landscape
- Novartis AG is a global pharmaceutical giant that produces various oncology treatments, including targeted therapies that compete for patient market share in the breast cancer treatment landscape.
- AstraZeneca PLC develops and markets several major cancer drugs, including those that target HER2-positive pathways and other genetic mutations common in aggressive tumors.
- Bristol-Myers Squibb Company offers a broad portfolio of oncology and immunotherapy products, competing with Puma for clinical trial placement and physician mindshare.
- Gilead Sciences, Inc. has expanded its presence in oncology through acquisitions, offering competing treatments for various solid tumors and hematological cancers.
- Merck & Co., Inc. is a leader in oncology with its blockbuster immunotherapy treatments, competing in the broader market for advanced and metastatic cancer care.
Strategic Outlook and Innovation
The strategic outlook for Puma Biotechnology is focused on maximizing the commercial potential of its approved indications while simultaneously expanding the clinical utility of its pipeline. The company is prioritizing studies that evaluate its therapies in combination with other established oncology drugs to improve patient outcomes and overcome resistance mechanisms in tumor cells. By focusing on precision medicine, the company aims to identify specific biomarkers that can predict which patients are most likely to benefit from its treatments.
Innovation at the company is driven by a deep understanding of molecular pathways and the biological drivers of cancer growth. The research team is dedicated to exploring the potential of its kinase inhibitors in rare tumor types where HER2 mutations play a significant role. Furthermore, the company is enhancing its patient support programs and educational initiatives to help clinicians manage the side effects associated with targeted therapies. This commitment to both scientific advancement and patient care is designed to solidify its position in the competitive oncology market.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | TLT covered calls | 1. | INTC covered calls | |
| 2. | SLV covered calls | 7. | HYG covered calls | 2. | QS covered calls | |
| 3. | IBIT covered calls | 8. | QQQ covered calls | 3. | OKLO covered calls | |
| 4. | GLD covered calls | 9. | KWEB covered calls | 4. | POET covered calls | |
| 5. | SPY covered calls | 10. | EEM covered calls | 5. | AXTI covered calls | |
Want more examples? PBW Covered Calls | PCAR Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
